Palatin Technologies Inc (PTN): Revenue
$0
Year ended 2025-06-30
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $0 | -100.0% | 2025-09-23, From 2024-07-01 |
| 2024-06-30 | $4.49M | -7.5% | 2025-09-23, From 2023-07-01 |
| 2023-06-30 | $4.85M | +230.5% | 2024-09-30, From 2022-07-01 |
| 2022-06-30 | $1.47M | n/m | 2023-09-28, From 2021-07-01 |
| 2021-06-30 | -$188.6K | n/m | 2022-09-22, From 2020-07-01 |
| 2020-06-30 | $118.0K | -99.8% | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | $60.30M | -10.2% | 2020-09-25, From 2018-07-01 |
| 2018-06-30 | $67.13M | n/c | 2019-09-12, From 2017-07-01 |
| 2017-06-30 | $67.13M | n/c | 2020-09-25, From 2016-07-01 |
| 2016-06-30 | $0 | n/a | 2018-09-13, From 2015-07-01 |
| No annual figure between 2013-06-30 and 2016-06-30. | |||
| 2013-06-30 | $10.4K | -85.9% | 2013-09-27, From 2012-07-01 |
| 2012-06-30 | $73.7K | -95.0% | 2013-09-27, From 2011-07-01 |
| 2011-06-30 | $1.48M | -89.6% | 2013-09-27, From 2010-07-01 |
| 2010-06-30 | $14.18M | n/a | 2012-09-10, From 2009-07-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Palatin Technologies Inc (PTN) | 2025-06-30 | $0 | -100.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $3.02M | +71.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
Compare PTN, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗